title: Prevalence and pathophysiology of impaired glucose tolerance in three different high-risk white groups.
abstract: Insulin resistance and beta-cell function were assessed by a continuous infusion of glucose in the following three groups of white subjects at risk of developing impaired glucose tolerance and diabetes: 41 subjects who were the offspring of patients with type II diabetes, 26 general-population subjects with an increased fasting plasma glucose level of at least 5.6 mmol/L on screening, and 22 subjects who had had gestational diabetes but were now nondiabetic. Subjects had a mean (+/- 1 SD) age of 43 +/- 9 years and a body mass index (BMI) of 27 +/- 5 kg/m2. Subjects with previously increased fasting glucose levels were significantly more insulin resistant than a control group, taking into account BMI, age, and gender (% normal insulin sensitivity [%], 59 [50 to 79] v 87 [73 to 96]; P < .005), and previously gestationally diabetic subjects showed greater impairment of beta-cell function (% normal beta-cell function [% beta], 69 [60 to 87] v 97 [89 to 105]; P < .005). Diabetes (defined by World Health Organization criteria) or impaired glucose tolerance (defined as an achieved plasma glucose concentration [APG] > 95th percentile of an age- and weight-matched population) was identified in 22% of family members, 31% of fasting hyperglycemic subjects, and 41% of previously gestationally diabetic subjects.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Diabetes Research Laboratories, Radcliffe Infirmary, Oxford, UK.
authors.forename: R C
authors.initials: RC
authors.lastname: Page
authors.forename: E K
authors.initials: EK
authors.lastname: Walravens
authors.forename: J C
authors.initials: JC
authors.lastname: Levy
authors.forename: I M
authors.initials: IM
authors.lastname: Stratton
authors.forename: R C
authors.initials: RC
authors.lastname: Turner
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001786:Blood Glucose / Q000378:metabolism*; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D005215:Fasting / Q000097:blood / Q000378:metabolism / Q000502:physiology; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism; D005951:Glucose Tolerance Test; D006801:Humans; D007262:Infusions, Intravenous; D007333:Insulin Resistance / Q000502:physiology*; D007515:Islets of Langerhans / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology; D010641:Phenotype; D015995:Prevalence; D011863:Radioimmunoassay; D012307:Risk Factors; D044465:White People
chemical_list: D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D005947:Glucose